Can-Fite BioPharma’s namodenoson was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma’s Lucrative Veterinary Licensing Deal
- Can-Fite BioPharma signs development, commercialization agreement with Vetbiolix
- Can-Fite Advances Pancreatic Cancer Drug Trial
- Can-Fite received approval from Israeli MoH to conduct Phase IIa trial
- Can-Fite BioPharma Launches $9M ADS Offering
